Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 31Triple Negative Breast Neoplasms 19Neoplasm Metastasis 5Urinary Bladder Neoplasms 4Carcinoma, Transitional Cell 4Carcinoma, Non-Small-Cell Lung 4Brain Neoplasms 4Salivary Gland Neoplasms 2Ovarian Neoplasms 2Lung Neoplasms 2Glioblastoma 2Colorectal Neoplasms 2Advanced Breast Cancer 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urothelial Bladder Carcinoma 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Oropharyngeal Neoplasms 1Neoplasm, Residual 1Muscle Invasive Bladder Urothelial Carcinoma 1Mouth Neoplasms 1Meningeal Carcinomatosis 1Lung Diseases 1Localized Muscle Invasive Bladder Urothelial Carcinoma 1

Interventions

Fulvestrant 5dalpiciclib 3Letrozole 3ribociclib 2palbociclib 2fluzoparib 2exemestane 2apatinib 2Anastrozole 2trastuzumab deruxtecan 1sacituzumab govitecan 1pyrotinib 1pegfilgrastim 1patritumab deruxtecan 1olaparib 1irinotecan sucrosofate 1abemaciclib 1Zoledronic Acid 1Rogaratinib 1Patient Reported Outcome Measures 1Paclitaxel 1Neoadjuvant Therapy 1Liposomes 1Irinotecan 1Ga(III)-DOTATOC 1Everolimus 1Cell Separation 1Capecitabine 1Bevacizumab 1Aromatase Inhibitors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Breast Cancer Metastatic × sacituzumab govitecan × Clear all
NCT06616987 2025-08-28

Prevention of Sacituzumab Govitecan-related Neutropenia in Patients With Metastatic Triple Negative Breast Cancer

Samsung Medical Center

Phase 2 Recruiting
40 enrolled
Breast

Breast Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡